HEARTLANDVENTURE NETWORKJoin the network
← Back to the newsroom
Deals & milestones

GT Metabolic announces undisclosed Series C led by J.P. Morgan

Sourced news brief · See the publication date above and original source below.

Minneapolis medical-device company GT Metabolic Solutions announced a Series C growth investment on October 28 led by J.P. Morgan Life Sciences Private Capital. The company did not disclose the amount, so the financing should not be included in a dollar total as though its size were known.

GT Metabolic develops magnetic-compression devices for creating gastrointestinal anastomoses. The company says the financing will support its global commercial launch, surgeon training, product development and expansion into additional surgical settings, including endoscopic and colorectal applications.

The release describes the investment as GT Metabolic’s first institutional financing partnership. It also attributes regulatory and performance claims to the company; this brief does not independently establish clinical superiority or a reduction in complication rates.

The next useful evidence will be adoption by providers, completed training and documented outcomes in authorized uses. The announcement establishes a new institutional investor and growth capital, but not the scale of that capital or the results of the planned expansion.

Continue reading

Your story could be next.

Share what you’re building ↗